Physician profile
James H Bates
NPI 1821092412
$712.14
in general payments reported to CMS, 2019-2025
11 companies · $280 in 2025
The $280 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88.64 · 2020: $25.30 · 2021: $240 · 2022: $41.32 · 2024: $36.86 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $316.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $163.27 | 2021-2025 | Repatha |
| Biohaven Pharmaceuticals, INC. | $157.44 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $122.01 | 2025 | |
| Abbvie INC. | $117.78 | 2021-2025 | |
| Mdd US Operations, LLC | $42.44 | 2019 | |
| Allergan, INC. | $26.26 | 2020-2021 | |
| Biodelivery Sciences International, INC. | $24.63 | 2020-2021 | |
| Pacira Therapeutics, INC. | $17.32 | 2019 | |
| Pfizer INC. | $14.65 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.23 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Bates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.